Royal Emerald Aims to Ramp Up Marijuana Production for Science
Published Date: 4/1/2026
Notice
Summary
Royal Emerald Pharmaceuticals wants to become a big-time maker of marijuana and related substances for research and medicine. People already registered or interested can share their thoughts or ask for a hearing by June 1, 2026. This move could boost the supply of these substances for scientific and medical use, with no extra fees mentioned yet.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06523 — Designation of P2P Methyl Glycidic Acid as a List I Chemical
Starting May 4, 2026, anyone handling P2P methyl glycidic acid—a key chemical used to make illegal drugs like methamphetamine—must follow new government rules and register with the DEA. This means all transactions, big or small, will be closely watched to stop illegal drug production. Businesses dealing with this chemical should act fast to stay legal and avoid penalties.
2026-06521 — Importer of Controlled Substances Application: Lipomed/LGC Standards
Lipomed/LGC Standards wants to become an official importer of certain controlled substances, like 3-Fluoro-N-methylcathinone. This means companies involved with these drugs can comment or ask for a hearing by May 4, 2026. If approved, it could impact how these substances enter the U.S., but no direct costs are mentioned yet.
2026-06051 — Importer of Controlled Substances Application: Usona Institute
Usona Institute wants to become an official importer of some powerful controlled substances like mescaline and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by April 29, 2026. This move could impact research and medical use, with no direct cost changes announced yet.
2026-05912 — Bulk Manufacturer of Controlled Substances Application: SpecGx LLC
SpecGx LLC wants to become a big-time maker of some powerful and tightly controlled drugs, including things like psilocybin and fentanyl. People and companies already registered can share their thoughts or ask for a hearing by May 26, 2026. This move could shake up how these substances are made and handled, so keep an eye on the deadlines if you’re involved!
2026-05618 — Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I
Starting April 22, 2026, the DEA is putting 3-methoxyphencyclidine (3-MeO-PCP) into Schedule I, meaning it’s now officially a highly controlled substance with strict rules. This affects anyone who makes, sells, studies, or even possesses 3-MeO-PCP, who will face serious legal consequences. This move helps the U.S. follow international drug laws and keeps communities safer.
2026-05486 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) just updated which chemical mixes are officially exempt from strict drug rules between September 2024 and December 2025. Companies and labs using these chemicals should check the new list to see if their products are approved or denied. You’ve got until May 19, 2026, to share your thoughts, and no extra fees are involved—just a quick review and comment if you want!
Previous / Next Documents
Previous: 2026-06255 — Joint Industry Plan; Order Approving an Amendment to the National Market System Plan Governing the Consolidated Audit Trail, as Modified by the Commission, To Further Reduce the Costs of the Consolidated Audit Trail
The SEC approved changes to the Consolidated Audit Trail (CAT) plan that help stock exchanges and regulators save money on tracking trades. These updates cut costs without slowing down how trade data is collected and shared. The new rules kick in soon, making the system cheaper and more efficient for everyone involved.
Next: 2026-06257 — Importer of Controlled Substances Application: Fisher Clinical Services, Inc.
Fisher Clinical Services, Inc. wants to become an official importer of certain controlled substances, including MDMA. People and companies involved with these drugs can share their thoughts or ask for a hearing by May 1, 2026. This move could impact how these substances are brought into the U.S., so keep an eye on the deadline if you want to speak up!
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in